Other analysts, such as Barclays Capital and Deutsche Bank, have also raised their targets for the company, which provides services for medication errors and hospital-acquired infections. CareFusion also maintains a consensus “Buy” rating and a price target of $34.27, according to the report.
More Articles on Infection Control:
Study: Cloth Towels Insufficient to Clean Hospital Rooms
Study: Printed Surgical Safety Checklist Improves Item Validation Rate
7 Action Items for Enhancing Patient Safety Data
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
